These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22291914)

  • 1. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods.
    Zhang J; Bowers J; Liu L; Wei S; Gowda GA; Hammoud Z; Raftery D
    PLoS One; 2012; 7(1):e30181. PubMed ID: 22291914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
    Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
    Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma.
    Zaidi AH; Gopalakrishnan V; Kasi PM; Zeng X; Malhotra U; Balasubramanian J; Visweswaran S; Sun M; Flint MS; Davison JM; Hood BL; Conrads TP; Bergman JJ; Bigbee WL; Jobe BA
    Cancer; 2014 Dec; 120(24):3902-13. PubMed ID: 25100294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.
    Shah AK; Cao KA; Choi E; Chen D; Gautier B; Nancarrow D; Whiteman DC; Saunders NA; Barbour AP; Joshi V; Hill MM
    Mol Cell Proteomics; 2015 Nov; 14(11):3023-39. PubMed ID: 26404905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic Evidence for a Field Effect in Histologically Normal and Metaplastic Tissues in Patients with Esophageal Adenocarcinoma.
    Reed MAC; Singhal R; Ludwig C; Carrigan JB; Ward DG; Taniere P; Alderson D; Günther UL
    Neoplasia; 2017 Mar; 19(3):165-174. PubMed ID: 28152423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
    Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.
    Bowers J; Hughes E; Skill N; Maluccio M; Raftery D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics study of esophageal adenocarcinoma.
    Zhang J; Liu L; Wei S; Nagana Gowda GA; Hammoud Z; Kesler KA; Raftery D
    J Thorac Cardiovasc Surg; 2011 Feb; 141(2):469-75, 475.e1-4. PubMed ID: 20880550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma.
    Schellnegger R; Quante A; Rospleszcz S; Schernhammer M; Höhl B; Tobiasch M; Pastula A; Brandtner A; Abrams JA; Strauch K; Schmid RM; Vieth M; Wang TC; Quante M
    Cancer Prev Res (Phila); 2017 Jan; 10(1):55-66. PubMed ID: 27807078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
    Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
    Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.
    Singhal S; Kapoor H; Subramanian S; Agrawal DK; Mittal SK
    J Gastrointest Cancer; 2019 Dec; 50(4):867-878. PubMed ID: 30187205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
    Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
    Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
    Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.
    Bus P; Kestens C; Ten Kate FJ; Peters W; Drenth JP; Roodhart JM; Siersema PD; van Baal JW
    J Gastroenterol; 2016 Jun; 51(6):560-70. PubMed ID: 26585599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ion mobility-mass spectrometry analysis of serum N-linked glycans from esophageal adenocarcinoma phenotypes.
    Gaye MM; Valentine SJ; Hu Y; Mirjankar N; Hammoud ZT; Mechref Y; Lavine BK; Clemmer DE
    J Proteome Res; 2012 Dec; 11(12):6102-10. PubMed ID: 23126309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.
    Mechref Y; Hussein A; Bekesova S; Pungpapong V; Zhang M; Dobrolecki LE; Hickey RJ; Hammoud ZT; Novotny MV
    J Proteome Res; 2009 Jun; 8(6):2656-66. PubMed ID: 19441788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.